UK drugmaker Shire is undertaking a voluntary market withdrawal of a limited portion of its Daytrana (methylphenidate transdermal system product. Shire is taking this action primarily due to feedback from patients and caregivers who have experienced difficulty removing the release liner from some Daytrana patches. Based on preliminary information, the retail value of product being withdrawn is estimated to be in the $4.0 million to $6.0 million range.
In the first quarter of 2007, Shire and the agent's US originator, USA-based Noven, implemented enhancements to the Daytrana release liner intended to improve ease of use of the patch, and product using the enhanced release liner is now in the trade channels. The firms say they are committed to improving the ease of use of Daytrana so patients can use its with the convenience they expect from this novel attention-deficit hyperactivity disorder treatment option.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze